Compare PCOR & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCOR | CORT |
|---|---|---|
| Founded | 2003 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 9.7B |
| IPO Year | 2020 | 2001 |
| Metric | PCOR | CORT |
|---|---|---|
| Price | $75.57 | $72.63 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 25 | 5 |
| Target Price | $69.86 | ★ $142.57 |
| AVG Volume (30 Days) | ★ 3.1M | 1.0M |
| Earning Date | 11-03-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 6.94 | N/A |
| EPS | 0.02 | ★ 1.13 |
| Revenue | ★ $1,322,509,000.00 | $761,407,000.00 |
| Revenue This Year | $14.75 | $52.09 |
| Revenue Next Year | $17.37 | $44.73 |
| P/E Ratio | $1,512.00 | ★ $70.11 |
| Revenue Growth | ★ 14.83 | 12.79 |
| 52 Week Low | $38.03 | $28.66 |
| 52 Week High | $80.41 | $126.38 |
| Indicator | PCOR | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 81.52 | 21.80 |
| Support Level | $46.64 | $30.24 |
| Resistance Level | N/A | $122.93 |
| Average True Range (ATR) | 2.79 | 6.22 |
| MACD | 1.48 | -2.44 |
| Stochastic Oscillator | 76.93 | 2.99 |
Procore Technologies Inc is a cloud-based construction management software company. It generates revenue through subscriptions for access to its software products. The company's products include Design Coordination, BIM, Field Productivity, Project Financials, Invoice Management, Portfolio Financials, Capital Planning, Accounting Integrations, and Analytics. The software products are hosted on its cloud-based SaaS construction management platform. Subscriptions are sold for a fixed fee and revenue is recognized ratably over the term of the subscription.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.